DE60142934D1 - Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung - Google Patents

Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung

Info

Publication number
DE60142934D1
DE60142934D1 DE60142934T DE60142934T DE60142934D1 DE 60142934 D1 DE60142934 D1 DE 60142934D1 DE 60142934 T DE60142934 T DE 60142934T DE 60142934 T DE60142934 T DE 60142934T DE 60142934 D1 DE60142934 D1 DE 60142934D1
Authority
DE
Germany
Prior art keywords
ring
substituents
production
optional
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142934T
Other languages
English (en)
Inventor
Samuel T Christian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Medical Innovations Inc
Original Assignee
International Medical Innovations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by International Medical Innovations Inc filed Critical International Medical Innovations Inc
Application granted granted Critical
Publication of DE60142934D1 publication Critical patent/DE60142934D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE60142934T 2000-04-12 2001-04-12 Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung Expired - Lifetime DE60142934D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/547,506 US6548484B1 (en) 2000-04-12 2000-04-12 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
PCT/US2001/011914 WO2001079244A1 (en) 2000-04-12 2001-04-12 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation

Publications (1)

Publication Number Publication Date
DE60142934D1 true DE60142934D1 (de) 2010-10-07

Family

ID=24184914

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142934T Expired - Lifetime DE60142934D1 (de) 2000-04-12 2001-04-12 Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung

Country Status (10)

Country Link
US (1) US6548484B1 (de)
EP (1) EP1385857B1 (de)
JP (1) JP2004523464A (de)
AT (1) ATE478885T1 (de)
AU (2) AU2001251565B2 (de)
CA (1) CA2443774C (de)
DE (1) DE60142934D1 (de)
HK (1) HK1063186A1 (de)
IL (1) IL158343A (de)
WO (1) WO2001079244A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9302982B2 (en) 2000-04-12 2016-04-05 Glycon Llc Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US20060189547A1 (en) * 2000-04-12 2006-08-24 Christian Samuel T Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use
US7345031B2 (en) * 2000-04-12 2008-03-18 International Medical Innovations, Inc. Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0111191D0 (en) * 2001-05-08 2001-06-27 Merck Sharp & Dohme Therapeutic agents
US7217696B2 (en) * 2002-02-28 2007-05-15 A & D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
EP1549323A2 (de) * 2002-05-07 2005-07-06 A & D Bioscience, Inc. Konjugate mit einem wirkstoff für das zentrale nervensystem
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
KR20050098246A (ko) * 2003-01-13 2005-10-11 뉴 리버 파마슈티칼스, 인크. 통제 물질의 남용 예방을 위한 탄수화물 접합체
WO2004110255A2 (en) * 2003-06-09 2004-12-23 Gang Zheng Antineoplastic agents targeted via glut transporters
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
WO2007016214A2 (en) * 2005-08-02 2007-02-08 Caritas St. Elizabeth's Medical Center Method for inhibiting tnf-alpha
KR101469538B1 (ko) * 2006-07-05 2014-12-05 시바 홀딩 인크 착색 유기 전기영동 입자
JP2008187927A (ja) * 2007-02-02 2008-08-21 Chiba Univ 新規なフェノール配糖化酵素
DE102007035642A1 (de) * 2007-07-30 2009-02-12 Grietje Beck Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen
EP2629609A4 (de) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Auf chemosensorischen rezeptorliganden basierende therapien
WO2014002039A1 (en) * 2012-06-27 2014-01-03 Shire Ag Amphetamine prodrugs
DE102017008073A1 (de) * 2017-08-28 2019-02-28 Henkel Ag & Co. Kgaa Neue anionische Tenside und Wasch- und Reinigungsmittel, welche diese enthalten
KR102482470B1 (ko) * 2019-04-11 2022-12-28 연세대학교 산학협력단 혈관 신생 촉진용 조성물 및 이의 제조 방법
CN115778930B (zh) * 2022-12-08 2024-02-27 陕西中医药大学 一种具有血管舒张活性的二硫缩醛类化合物在制备具有血管舒张活性药物方面的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2595405A (en) 1952-05-06 Their production
US2427878A (en) 1947-04-08 1947-09-23 Parke Davis & Co Dialkylaminopropyl ethers of benzhydrol
US2599000A (en) 1950-09-02 1952-06-03 Smith Kline French Lab Nu, nu-disubstituted-beta-halo-alkylamines
US2682543A (en) 1951-05-26 1954-06-29 Burroughs Wellcome Co Catalytic reduction of diphenyl alkanolamines and resulting products
US2789110A (en) 1953-03-14 1957-04-16 Knoll Ag Amino alcohols substituted by bicycloalkyl residues and a process of making same
US2891890A (en) 1954-02-19 1959-06-23 Burroughs Wellcome Co Method of treating parkinsonism
US3462536A (en) 1960-07-22 1969-08-19 Merck & Co Inc Method of inhibiting decarboxylase
US3253023A (en) 1963-09-27 1966-05-24 Dow Chemical Co Recovery of 3-(3, 4-dihydroxyphenyl)-l-alanine from velvet beans
US3405159A (en) 1964-11-17 1968-10-08 Merck & Co Inc Process for resolving racemic mixtures of optically-active enantiomorphs
CH507249A (de) 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
US4016280A (en) 1969-07-17 1977-04-05 Byk Gulden Lomberg Chemische Fabrik Gmbh 4,4-Diarylpiperidine compositions and use
US3962447A (en) 1973-12-26 1976-06-08 Interx Research Corporation Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and method of using same
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
US4166182A (en) 1978-02-08 1979-08-28 Eli Lilly And Company 6-n-propyl-8-methoxymethyl or methylmercaptomethylergolines and related compounds
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
JP2682713B2 (ja) * 1988-12-27 1997-11-26 田辺製薬株式会社 光学活性テトラヒドロフランの製法
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5180716A (en) 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
ZA923283B (en) 1991-05-29 1993-01-27 Akzo Nv Phenoxyphenyl derivatives
US5639737A (en) * 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
ATE397005T1 (de) * 1996-01-30 2008-06-15 Glycomimetics Inc Sialyl-lewisa und sialyl-lewisx epitope analoge
JP5159274B2 (ja) 2006-11-30 2013-03-06 パナソニック株式会社 無線送信装置及び無線送信方法
US8220897B2 (en) 2009-12-23 2012-07-17 Xerox Corporation Computer based method and system for adjusting page placement on a continuous feed print engine

Also Published As

Publication number Publication date
WO2001079244A1 (en) 2001-10-25
US6548484B1 (en) 2003-04-15
CA2443774C (en) 2009-11-24
EP1385857A1 (de) 2004-02-04
CA2443774A1 (en) 2001-10-25
EP1385857B1 (de) 2010-08-25
ATE478885T1 (de) 2010-09-15
JP2004523464A (ja) 2004-08-05
IL158343A (en) 2010-11-30
EP1385857A4 (de) 2006-09-06
AU2001251565B2 (en) 2006-09-28
HK1063186A1 (en) 2004-12-17
IL158343A0 (en) 2004-05-12
AU5156501A (en) 2001-10-30

Similar Documents

Publication Publication Date Title
DE60142934D1 (de) Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung
ATE366249T1 (de) Zyklische amid-derivate
DK1140916T3 (da) Heteroaryl-cykliske acetaler
TW200606137A (en) Urea derivatives
ATE556058T1 (de) 1-(2h)-isochinolonderivat
TR200402300T4 (tr) İmidazopirimidin türevleri ve triazolopirimidin türevleri.
NO994452D0 (no) Substituerte 4-arylmetylen-2-imino-2,3-dihydrotiazoler og derivater, og deres farmasöytiske anvendelse
DE69827785D1 (de) 1,4-substituierte cyclische aminderivate
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TR199901933T1 (xx) 3-Piperidil-4-oksokuinazolin t�revleri ve bunlar� i�eren farmas�tik terkipler.
HUP9800051A2 (hu) 1-Aril-2-acil-amino-etán-vegyületek, alkalmazásuk neurokinin-antagonista gyógyszerkészítmények előállítására és a vegyületeket tartalmazó gyógyszerkészítmények
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
ATE276257T1 (de) Pyrazinonderivate
TW200735867A (en) Medicine comprising substituted urea derivative
MA28259A1 (fr) Derives de piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR960029312A (ko) N-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
WO2001062709A3 (de) Verwendung von 2-phenylendiaminderivaten zur behandlung von infektionen
HUP9900883A2 (hu) Helyettesített kinoxalin 2,3-dion származékok aminosav származékai, mint glutamát receptor antagonista vegyületek
TR200103215T2 (tr) 6-[[(Aril ve heteroaril)oksi]metil]naftalin-2-karboksimidamid türevleri, bunların hazırlanması ve terapötik uygulamaları
DE60237652D1 (de) Variolinderivate und ihre Verwendung als Cytostatika
DE69626624D1 (de) Medikamente gegen trhombocytopenie
DE69624459D1 (de) Kondensierte indan-derivate und ihre salze
DE60116655D1 (de) Carbamatderivate, verfahren zu deren herstellung und deren verwendung
EA200900922A1 (ru) НОВЫЕ СОЕДИНЕНИЯ ТРИАЗАБЕНЗО[α]НАФТО[2,1,8-cde]АЗУЛЕНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ